US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Q32 Bio Inc.

3.41

-0.4100-10.73%

Post-market: 3.410.00000.00%18:20 EST

Volume:6.43M

Turnover:24.46M

Market Cap:41.59M

PE:-0.52

High:3.93

Open:3.80

Low:3.23

Close:3.82

52wk High:28.06

52wk Low:1.35

Shares:12.20M

Float Shares:4.73M

Volume Ratio:0.19

T/O Rate:135.91%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-6.5785

EPS(LYR):-5.1211

ROE:-491.67%

ROA:-33.50%

PB:-2.25

PE(LYR):-0.67

Loading ...

Overview Company News Filings

Q32 Bio Inc - Q3 Net Loss $7.4 Mln

THOMSON REUTERS

Q32 Bio Inc Qtrly EPS $-0.60

THOMSON REUTERS

Q32 Bio Inc: Cash and Cash Equivalents Sufficient to Fund Operations Into 2027

THOMSON REUTERS

Q32 Bio Inc expected to post a loss of $1.19 a share - Earnings Preview

Q32 Bio Completes Enrollment in Phase 2a Alopecia Areata Trial of Bempikibart

Q32 Bio Announces Completion of Enrollment in Part B of Signal-Aa Phase 2a Clinical Trial of Bempikibart for Alopecia Areata

THOMSON REUTERS

Q32 Bio Inc - Topline Data From Signal-Aa Part B Expected Mid-2026

THOMSON REUTERS

CEO Jodie Pope Morrison Reports Disposal of Common Shares of Q32 Bio Inc

Chief Scientific Officer Shelia M. Violette Reports Disposal of Common Shares of Q32 Bio Inc

CFO and President Lee Kalowski Reports Disposal of Common Shares of Q32 Bio Inc

Q32 Bio Inc. to Present at Wells Fargo Healthcare Conference

BRIEF-Q32 Bio Reports Second Quarter 2025 Financial Results And Provides Corporate Update

Q32 Bio Q2 EPS $(0.78) Beats $(1.29) Estimate

Q32 Bio Inc. Reports Q2 2025 Results: Net Loss Reduces to $9.5M, EPS Improves to $0.78 Loss from $1.42 Loss in Previous Year

Q32 Bio Inc: Q2 EPS $0.78

THOMSON REUTERS

Q32 Bio Inc expected to post a loss of 98 cents a share - Earnings Preview

Top Premarket Decliners

MT Newswires Live

Inventiva Names Jason Campagna Chief Medical Officer

MT Newswires Live

Inventiva SA Appoints Jason Campagna as Chief Medical Officer and Martine Zimmermann as EVP of Regulatory Affairs Amid Leadership Transition

Press Release: Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/QTTB/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"QTTB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"QTTB\",,,,,undefined,":{"symbol":"QTTB","market":"US","secType":"STK","nameCN":"Q32 Bio Inc.","latestPrice":3.41,"timestamp":1764709200000,"preClose":3.82,"halted":0,"volume":6426868,"hourTrading":{"tag":"盘后","latestPrice":3.41,"preClose":3.41,"latestTime":"18:20 EST","volume":39771,"amount":133199.0724897,"timestamp":1764717636110},"delay":0,"floatShares":4728923,"shares":12197615,"eps":-6.578484,"marketStatus":"Post-Mkt","change":-0.41,"latestTime":"12-02 18:21:04 EST","open":3.8,"high":3.93,"low":3.23,"amount":24460924.3949616,"amplitude":0.183246,"askPrice":3.41,"askSize":691,"bidPrice":3.37,"bidSize":8,"shortable":0,"etf":0,"ttmEps":-6.578484,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1764723600000},"marketStatusCode":4,"adr":0,"listingDate":1522209600000,"exchange":"NASDAQ","adjPreClose":3.82,"preHourTrading":{"tag":"盘前","latestPrice":3.8,"preClose":3.82,"latestTime":"09:29 EST","volume":1034927,"amount":4200399.5345391,"timestamp":1764685799018},"postHourTrading":{"tag":"盘后","latestPrice":3.41,"preClose":3.41,"latestTime":"18:20 EST","volume":39771,"amount":133199.0724897,"timestamp":1764717636110},"volumeRatio":0.190971,"impliedVol":0.4864,"impliedVolPercentile":0.5568},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"QTTB\",,,,,undefined,":{"symbol":"QTTB","floatShares":4728923,"roa":"-33.50%","roe":"-491.67%","lyrEps":-5.12108,"volumeRatio":0.190971,"shares":12197615,"dividePrice":0,"high":3.93,"amplitude":0.183246,"preClose":3.82,"low":3.23,"week52Low":1.345,"pbRate":"-2.25","psRate":"-2.84","week52High":28.06,"institutionHeld":0,"latestPrice":3.41,"committee":-0.97711,"eps":-6.578484,"divideRate":0,"volume":6426868,"delay":0,"ttmEps":-6.578484,"open":3.8,"prevYearClose":3.44,"prevWeekClose":2.19,"prevMonthClose":2.19,"prevQuarterClose":1.98,"fiveDayClose":2.04,"twentyDayClose":2.57,"sixtyDayClose":1.75},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/QTTB\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-13","symbol":"QTTB","fiscalQuarterEnding":"2025/09","expectedEps":-1.39,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"pre","actualEps":-0.6},{"market":"US","date":"2025-08-06","symbol":"QTTB","fiscalQuarterEnding":"2025/06","expectedEps":-1.14,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1754452800000,"reportTimeType":"pre","actualEps":-0.78},{"market":"US","date":"2025-03-11","symbol":"QTTB","fiscalQuarterEnding":"2024/12","expectedEps":-1.49,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1741665600000,"reportTimeType":"pre","actualEps":-1.16},{"market":"US","date":"2024-05-09","symbol":"QTTB","fiscalQuarterEnding":"2024/03","expectedEps":-1.42,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715227200000,"reportTimeType":"pre","actualEps":-13.15},{"market":"US","date":"2024-03-26","symbol":"QTTB","defaultRemindTime":1711459800000,"type":"split","dateTimestamp":1711425600000,"forFactor":18,"toFactor":1,"ratio":18}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"QTTB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"QTTB\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0,"hold":0.75,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0,"analysts":4,"updateTime":1739332800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/QTTB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"QTTB","date":"2025-12-01","current":-0.580681,"percent":0.518703,"low":-10.694771,"twenty":-6.809794,"median":-0.654062,"eighty":-0.422683,"high":-0.277436,"avg":-3.205511,"sd":3.565119,"marketCap":26946530},"quantilePoints":[{"date":"2024-04-05","current":-4.597074,"twenty":-4.75645,"median":-4.597074,"eighty":-3.952906,"marketCap":247060524},{"date":"2024-04-12","current":-5.285192,"twenty":-4.79019,"median":-4.726928,"eighty":-4.38975,"marketCap":284042061},{"date":"2024-04-19","current":-5.411717,"twenty":-5.438798,"median":-4.767993,"eighty":-4.57532,"marketCap":290841892},{"date":"2024-04-26","current":-6.268535,"twenty":-5.702502,"median":-5.138689,"eighty":-4.700069,"marketCap":336889870},{"date":"2024-05-03","current":-5.72026,"twenty":-5.938238,"median":-5.411717,"eighty":-4.727594,"marketCap":307423936},{"date":"2024-05-10","current":-5.948893,"twenty":-5.966207,"median":-5.603724,"eighty":-4.749348,"marketCap":319711350},{"date":"2024-05-17","current":-6.881182,"twenty":-6.171755,"median":-5.72026,"eighty":-4.765329,"marketCap":369815368},{"date":"2024-05-24","current":-6.526024,"twenty":-6.419477,"median":-5.852334,"eighty":-4.856783,"marketCap":350728123},{"date":"2024-05-31","current":-7.119566,"twenty":-6.557988,"median":-5.896729,"eighty":-4.946904,"marketCap":326617228},{"date":"2024-06-07","current":-5.417118,"twenty":-6.655355,"median":-5.948893,"eighty":-5.16799,"marketCap":248515704},{"date":"2024-06-14","current":-5.122964,"twenty":-6.625166,"median":-5.89118,"eighty":-5.079231,"marketCap":235021098},{"date":"2024-06-21","current":-4.172821,"twenty":-6.589953,"median":-5.833467,"eighty":-4.901621,"marketCap":191432327},{"date":"2024-06-28","current":-3.969777,"twenty":-6.557988,"median":-5.738018,"eighty":-4.86516,"marketCap":182117467},{"date":"2024-07-05","current":-4.511228,"twenty":-6.526024,"median":-5.680305,"eighty":-4.760002,"marketCap":206957095},{"date":"2024-07-12","current":-5.841429,"twenty":-6.49406,"median":-5.603724,"eighty":-4.798567,"marketCap":267981374},{"date":"2024-07-15","current":-6.825412,"twenty":-6.526024,"median":-5.660327,"eighty":-4.813855,"marketCap":313122622},{"date":"2024-08-02","current":-9.884093,"twenty":-6.542006,"median":-5.670316,"eighty":-4.829142,"marketCap":453442638},{"date":"2024-08-09","current":-7.500596,"twenty":-6.710706,"median":-5.738018,"eighty":-4.87207,"marketCap":427886482},{"date":"2024-08-16","current":-7.75207,"twenty":-6.825412,"median":-5.856316,"eighty":-4.928392,"marketCap":442232352},{"date":"2024-08-23","current":-8.155846,"twenty":-7.24299,"median":-5.902278,"eighty":-4.94491,"marketCap":465266543},{"date":"2024-08-30","current":-8.295371,"twenty":-7.548702,"median":-6.028804,"eighty":-4.98294,"marketCap":473226002},{"date":"2024-09-06","current":-9.684274,"twenty":-7.772364,"median":-6.120922,"eighty":-4.998807,"marketCap":552458796},{"date":"2024-09-13","current":-9.610284,"twenty":-8.191784,"median":-6.244914,"eighty":-5.018839,"marketCap":548237871},{"date":"2024-09-20","current":-9.971779,"twenty":-8.294103,"median":-6.360654,"eighty":-5.041746,"marketCap":568860105},{"date":"2024-09-27","current":-9.599714,"twenty":-8.935493,"median":-6.526024,"eighty":-5.050076,"marketCap":547634882},{"date":"2024-10-04","current":-9.037388,"twenty":-9.107996,"median":-6.621961,"eighty":-5.093809,"marketCap":515555851},{"date":"2024-10-11","current":-9.978122,"twenty":-9.382394,"median":-6.703603,"eighty":-5.220301,"marketCap":569221899},{"date":"2024-10-18","current":-10.49394,"twenty":-9.484712,"median":-6.794175,"eighty":-5.315929,"marketCap":598647777},{"date":"2024-10-25","current":-10.06691,"twenty":-9.672968,"median":-6.825412,"eighty":-5.346971,"marketCap":574287009},{"date":"2024-10-31","current":-9.792089,"twenty":-9.748541,"median":-7.119566,"eighty":-5.360507,"marketCap":558609287},{"date":"2024-11-08","current":-9.443128,"twenty":-9.802236,"median":-7.283651,"eighty":-5.372344,"marketCap":572357443},{"date":"2024-11-15","current":-7.16039,"twenty":-9.789552,"median":-7.500596,"eighty":-5.379633,"marketCap":433998376},{"date":"2024-11-22","current":-5.434099,"twenty":-9.773909,"median":-7.256318,"eighty":-5.396215,"marketCap":329366155},{"date":"2024-11-29","current":-5.407973,"twenty":-9.752346,"median":-7.139978,"eighty":-5.371303,"marketCap":327782663},{"date":"2024-12-06","current":-4.760865,"twenty":-9.734588,"median":-6.825412,"eighty":-5.339276,"marketCap":288560806},{"date":"2024-12-13","current":-0.854102,"twenty":-9.716407,"median":-6.794175,"eighty":-5.114636,"marketCap":51767979},{"date":"2024-12-20","current":-0.671224,"twenty":-9.680505,"median":-6.703603,"eighty":-5.031844,"marketCap":40683541},{"date":"2024-12-27","current":-0.719455,"twenty":-9.66543,"median":-6.637987,"eighty":-4.975898,"marketCap":43606909},{"date":"2025-01-03","current":-0.69333,"twenty":-9.621313,"median":-6.605935,"eighty":-4.929676,"marketCap":42023418},{"date":"2025-01-10","current":-0.657156,"twenty":-9.603942,"median":-6.526024,"eighty":-4.86516,"marketCap":39830892},{"date":"2025-01-17","current":-0.631031,"twenty":-9.545173,"median":-6.362567,"eighty":-4.746844,"marketCap":38247401},{"date":"2025-01-24","current":-0.677253,"twenty":-9.492745,"median":-6.288512,"eighty":-4.6939,"marketCap":41048962},{"date":"2025-01-31","current":-0.655147,"twenty":-9.465263,"median":-6.219701,"eighty":-4.511228,"marketCap":39709085},{"date":"2025-02-07","current":-0.63505,"twenty":-9.453365,"median":-6.05877,"eighty":-3.980076,"marketCap":38491015},{"date":"2025-02-14","current":-0.538587,"twenty":-9.43896,"median":-5.948893,"eighty":-0.813105,"marketCap":32644278},{"date":"2025-02-21","current":-0.488345,"twenty":-9.423405,"median":-5.89118,"eighty":-0.724279,"marketCap":29599103},{"date":"2025-02-28","current":-0.450162,"twenty":-9.384931,"median":-5.843753,"eighty":-0.704182,"marketCap":27284770},{"date":"2025-03-07","current":-0.468249,"twenty":-9.351106,"median":-5.738018,"eighty":-0.689713,"marketCap":28381033},{"date":"2025-03-14","current":-0.470191,"twenty":-9.227225,"median":-5.670316,"eighty":-0.675243,"marketCap":22443611},{"date":"2025-03-21","current":-0.53152,"twenty":-9.18875,"median":-5.509385,"eighty":-0.665195,"marketCap":25371039},{"date":"2025-03-28","current":-0.482968,"twenty":-9.161872,"median":-5.425609,"eighty":-0.655147,"marketCap":23053492},{"date":"2025-04-04","current":-0.408861,"twenty":-9.091808,"median":-5.407973,"eighty":-0.643893,"marketCap":19516184},{"date":"2025-04-11","current":-0.429305,"twenty":-9.050837,"median":-5.380674,"eighty":-0.631433,"marketCap":20491993},{"date":"2025-04-17","current":-0.472746,"twenty":-9.045443,"median":-5.362133,"eighty":-0.622992,"marketCap":22565587},{"date":"2025-04-25","current":-0.472746,"twenty":-9.037388,"median":-5.336421,"eighty":-0.57878,"marketCap":22565587},{"date":"2025-05-02","current":-0.39864,"twenty":-8.919003,"median":-5.165991,"eighty":-0.546852,"marketCap":19028279},{"date":"2025-05-09","current":-0.314156,"twenty":-8.857697,"median":-5.050076,"eighty":-0.534567,"marketCap":18784327},{"date":"2025-05-16","current":-0.354955,"twenty":-8.778159,"median":-5.035734,"eighty":-0.528965,"marketCap":21223850},{"date":"2025-05-23","current":-0.336596,"twenty":-8.694918,"median":-4.992187,"eighty":-0.51491,"marketCap":20126064},{"date":"2025-05-30","current":-0.385555,"twenty":-8.584144,"median":-4.945951,"eighty":-0.506094,"marketCap":23053492},{"date":"2025-06-06","current":-0.375355,"twenty":-8.389867,"median":-4.923647,"eighty":-0.48773,"marketCap":22443611},{"date":"2025-06-13","current":-0.346796,"twenty":-8.305941,"median":-4.87898,"eighty":-0.485012,"marketCap":20735945},{"date":"2025-06-20","current":-0.325376,"twenty":-8.294103,"median":-4.767993,"eighty":-0.472746,"marketCap":19455195},{"date":"2025-06-27","current":-0.316196,"twenty":-8.276767,"median":-4.744886,"eighty":-0.463426,"marketCap":18906303},{"date":"2025-07-03","current":-0.293756,"twenty":-8.257318,"median":-4.726928,"eighty":-0.447751,"marketCap":17564565},{"date":"2025-07-11","current":-0.677271,"twenty":-8.238715,"median":-4.597074,"eighty":-0.434085,"marketCap":40496081},{"date":"2025-07-18","current":-0.473274,"twenty":-8.204468,"median":-4.511228,"eighty":-0.43275,"marketCap":28298466},{"date":"2025-07-25","current":-0.471234,"twenty":-8.162188,"median":-4.172821,"eighty":-0.434085,"marketCap":28176490},{"date":"2025-08-01","current":-0.452874,"twenty":-8.09158,"median":-3.876104,"eighty":-0.433118,"marketCap":27078705},{"date":"2025-08-08","current":-0.417439,"twenty":-7.990847,"median":-0.854102,"eighty":-0.431093,"marketCap":21833730},{"date":"2025-08-15","current":-0.438428,"twenty":-7.911731,"median":-0.739552,"eighty":-0.423091,"marketCap":22931516},{"date":"2025-08-22","current":-0.437262,"twenty":-7.782512,"median":-0.719455,"eighty":-0.423091,"marketCap":22870528},{"date":"2025-08-29","current":-0.412775,"twenty":-7.72332,"median":-0.705388,"eighty":-0.422172,"marketCap":21589778},{"date":"2025-09-05","current":-0.387122,"twenty":-7.662014,"median":-0.692325,"eighty":-0.419594,"marketCap":20248040},{"date":"2025-09-12","current":-0.438428,"twenty":-7.579145,"median":-0.689311,"eighty":-0.417439,"marketCap":22931516},{"date":"2025-09-19","current":-0.405779,"twenty":-7.530963,"median":-0.677262,"eighty":-0.417439,"marketCap":21223850},{"date":"2025-09-26","current":-0.438428,"twenty":-7.458231,"median":-0.675243,"eighty":-0.417439,"marketCap":22931516},{"date":"2025-10-03","current":-0.482737,"twenty":-7.286722,"median":-0.66821,"eighty":-0.417768,"marketCap":25249063},{"date":"2025-10-10","current":-0.755588,"twenty":-7.269646,"median":-0.665195,"eighty":-0.419083,"marketCap":39520272},{"date":"2025-10-17","current":-0.839542,"twenty":-7.219361,"median":-0.673234,"eighty":-0.419594,"marketCap":43911414},{"date":"2025-10-24","current":-0.652977,"twenty":-7.152225,"median":-0.675243,"eighty":-0.421731,"marketCap":34153322},{"date":"2025-10-31","current":-0.643649,"twenty":-7.071889,"median":-0.671224,"eighty":-0.422103,"marketCap":33665417},{"date":"2025-11-07","current":-0.541038,"twenty":-6.870028,"median":-0.665195,"eighty":-0.422103,"marketCap":28298466},{"date":"2025-11-14","current":-0.515386,"twenty":-6.825412,"median":-0.656232,"eighty":-0.422103,"marketCap":26956729},{"date":"2025-11-21","current":-0.564098,"twenty":-6.824371,"median":-0.655309,"eighty":-0.422137,"marketCap":23747399},{"date":"2025-11-28","current":-0.640091,"twenty":-6.820206,"median":-0.655147,"eighty":-0.422275,"marketCap":26946530},{"date":"2025-12-01","current":-0.640091,"twenty":-6.809794,"median":-0.654062,"eighty":-0.422683,"marketCap":26946530}],"updateTime":1764682079821},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"QTTB\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2583564768","title":"Q32 Bio Inc - Q3 Net Loss $7.4 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2583564768","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583564768?lang=en_us&edition=fundamental","pubTime":"2025-11-13 19:59","pubTimestamp":1763035140,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nTUA5GVW4S:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","QTTB"],"gpt_icon":0},{"id":"2583564430","title":"Q32 Bio Inc Qtrly EPS $-0.60","url":"https://stock-news.laohu8.com/highlight/detail?id=2583564430","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583564430?lang=en_us&edition=fundamental","pubTime":"2025-11-13 19:59","pubTimestamp":1763035140,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nTUA5GVW4S:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["QTTB","BK4139"],"gpt_icon":0},{"id":"2583050564","title":"Q32 Bio Inc: Cash and Cash Equivalents Sufficient to Fund Operations Into 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2583050564","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583050564?lang=en_us&edition=fundamental","pubTime":"2025-11-13 19:59","pubTimestamp":1763035140,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nTUA5GVW4S:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","QTTB"],"gpt_icon":0},{"id":"2580219461","title":"Q32 Bio Inc  expected to post a loss of $1.19 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2580219461","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580219461?lang=en_us&edition=fundamental","pubTime":"2025-11-03 22:13","pubTimestamp":1762179186,"startTime":"0","endTime":"0","summary":"Q32 Bio Inc  expected to post a loss of $1.19 a share - Earnings Preview Q32 Bio Inc QTTB.OQ QTTB.O is expected to  show no change in quarterly revenue when it reports  results on November 5 (estimate","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nL8N3WF19G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QTTB","BK4139"],"gpt_icon":0},{"id":"2577154821","title":"Q32 Bio Completes Enrollment in Phase 2a Alopecia Areata Trial of Bempikibart","url":"https://stock-news.laohu8.com/highlight/detail?id=2577154821","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577154821?lang=en_us&edition=fundamental","pubTime":"2025-10-21 18:59","pubTimestamp":1761044356,"startTime":"0","endTime":"0","summary":"Q32 Bio Inc. has announced the completion of enrollment in Part B of its SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with severe or very severe alopecia areata . The trial enrolled a total of 33 patients, exceeding the initial target of approximately 20 due to increased demand. Bempikibart is a fully human anti-IL-7Rα antibody designed to block IL-7 and TSLP signaling. Preliminary pharmacokinetic data indicate that steady state drug concentration in patients is achieved at least nine weeks earlier in Part B compared to Part A, due to the inclusion of a loading regimen. Topline results from Part B of the SIGNAL-AA trial are expected to be reported in mid-2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Q32 B","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251021:nNDLrTbRc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QTTB","BK4139"],"gpt_icon":0},{"id":"2577821589","title":"Q32 Bio Announces Completion of Enrollment in Part B of Signal-Aa Phase 2a Clinical Trial of Bempikibart for Alopecia Areata","url":"https://stock-news.laohu8.com/highlight/detail?id=2577821589","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577821589?lang=en_us&edition=fundamental","pubTime":"2025-10-21 18:59","pubTimestamp":1761044340,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251021:nTUA5T0HW7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["QTTB","BK4139"],"gpt_icon":0},{"id":"2577110821","title":"Q32 Bio Inc - Topline Data From Signal-Aa Part B Expected Mid-2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2577110821","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577110821?lang=en_us&edition=fundamental","pubTime":"2025-10-21 18:59","pubTimestamp":1761044340,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251021:nTUA5T0HW7:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","QTTB"],"gpt_icon":0},{"id":"2563150060","title":"CEO Jodie Pope Morrison Reports Disposal of Common Shares of Q32 Bio Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2563150060","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563150060?lang=en_us&edition=fundamental","pubTime":"2025-08-29 07:33","pubTimestamp":1756423983,"startTime":"0","endTime":"0","summary":"Jodie Pope Morrison, CEO and Director of Q32 Bio Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Q32 Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 28, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250828:nNDLbwQQm1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QTTB","BK4139"],"gpt_icon":0},{"id":"2563060653","title":"Chief Scientific Officer Shelia M. Violette Reports Disposal of Common Shares of Q32 Bio Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2563060653","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563060653?lang=en_us&edition=fundamental","pubTime":"2025-08-29 07:28","pubTimestamp":1756423739,"startTime":"0","endTime":"0","summary":"Shelia M. Violette, Chief Scientific Officer at Q32 Bio Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Q32 Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 28, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250828:nNDLbZhd1B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QTTB","BK4139"],"gpt_icon":0},{"id":"2563578060","title":"CFO and President Lee Kalowski Reports Disposal of Common Shares of Q32 Bio Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2563578060","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563578060?lang=en_us&edition=fundamental","pubTime":"2025-08-29 07:21","pubTimestamp":1756423282,"startTime":"0","endTime":"0","summary":"Lee Kalowski, CFO and President of Q32 Bio Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Q32 Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 28, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250828:nNDL1FGGmP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QTTB","BK4139"],"gpt_icon":0},{"id":"2562116035","title":"Q32 Bio Inc. to Present at Wells Fargo Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2562116035","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562116035?lang=en_us&edition=fundamental","pubTime":"2025-08-28 18:59","pubTimestamp":1756378759,"startTime":"0","endTime":"0","summary":"Q32 Bio Inc., a clinical stage biotechnology company, will participate in a fireside chat at the 2025 Wells Fargo Healthcare Conference. The event is scheduled for 3:45 p.m. E.T. on Thursday, September 4th. Q32 Bio is focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases. A webcast of the presentation will be available on Q32 Bio's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Q32 Bio Inc. published the original content used to generate this news brief via PR Newswire  on August 28, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250828:nNDL7zvJF5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","QTTB"],"gpt_icon":0},{"id":"2557377943","title":"BRIEF-Q32 Bio Reports Second Quarter 2025 Financial Results And Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2557377943","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557377943?lang=en_us&edition=fundamental","pubTime":"2025-08-06 21:15","pubTimestamp":1754486124,"startTime":"0","endTime":"0","summary":"BRIEF-Q32 Bio Reports Second Quarter 2025 Financial Results And Provides Corporate UpdateAug 6 (Reuters) - Q32 Bio Inc QTTB.O:Q32 BIO REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORA","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250806:nTUA88QCK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QTTB","BK4139"],"gpt_icon":0},{"id":"2557372881","title":"Q32 Bio Q2 EPS $(0.78) Beats $(1.29) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2557372881","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557372881?lang=en_us&edition=fundamental","pubTime":"2025-08-06 20:37","pubTimestamp":1754483869,"startTime":"0","endTime":"0","summary":"Q32 Bio (NASDAQ:QTTB) reported quarterly losses of $(0.78) per share which beat the analyst consensus estimate of $(1.29) by 39.53 percent. This is a 45.07 percent increase over losses of $(1.42) per share from the same","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/08/46897200/q32-bio-q2-eps-0-78-beats-1-29-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QTTB"],"gpt_icon":0},{"id":"2557637639","title":"Q32 Bio Inc. Reports Q2 2025 Results: Net Loss Reduces to $9.5M, EPS Improves to $0.78 Loss from $1.42 Loss in Previous Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2557637639","media":"Reuters","labels":["dataReport","event","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557637639?lang=en_us&edition=fundamental","pubTime":"2025-08-06 18:59","pubTimestamp":1754477957,"startTime":"0","endTime":"0","summary":"Q32 Bio Inc., a clinical stage biotechnology company, has released its financial results for the second quarter of 2025. The company reported cash and cash equivalents of $54.8 million as of June 30, 2025, which it expects to be sufficient to fund operations into 2027. The net loss for the three-month period ended June 30, 2025, was $9.5 million, compared to a net loss of $17.0 million for the same period in 2024. The reduction in net loss is reflected in a decrease in research and development expenses, which fell to $5.2 million from $13.4 million in the prior year, primarily due to lower bempikibart development costs and restructuring actions. General and administrative expenses also decreased to $4.0 million from $4.5 million, attributed to reduced headcount and legal costs. The company is continuing its development program for bempikibart, with patient dosing ongoing in the Part A open-label extension and Part B of the SIGNAL-AA trial. The topline data readout for Part B is on trac","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250806:nNDL6nxH1m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,event,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QTTB"],"gpt_icon":0},{"id":"2557560375","title":"Q32 Bio Inc: Q2 EPS $0.78","url":"https://stock-news.laohu8.com/highlight/detail?id=2557560375","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557560375?lang=en_us&edition=fundamental","pubTime":"2025-08-06 18:59","pubTimestamp":1754477943,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250806:nTUA88QCK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","QTTB"],"gpt_icon":0},{"id":"2556843523","title":"Q32 Bio Inc  expected to post a loss of 98 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2556843523","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556843523?lang=en_us&edition=fundamental","pubTime":"2025-08-04 20:55","pubTimestamp":1754312107,"startTime":"0","endTime":"0","summary":"Q32 Bio Inc  expected to post a loss of98cents a share - Earnings Preview Q32 Bio Inc QTTB.OQ QTTB.O is expected to  show no change in quarterly revenue when it reports  results on August 6 (estimated","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250804:nL8N3TW113:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QTTB"],"gpt_icon":0},{"id":"2550581219","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2550581219","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550581219?lang=en_us&edition=fundamental","pubTime":"2025-07-11 19:47","pubTimestamp":1752234420,"startTime":"0","endTime":"0","summary":"Capricor Therapeutics  shares were down nearly 49% pre-bell Friday after the company said that the US Food and Drug Administration has required additional clinical data on deramiocel, a cell therapy candidate for cardiomyopathy in Duchenne muscular dystrophy patients.Q32 Bio  shares were 31% lower, erasing part of Thursday's rally.Concorde International  stock was down 28%, extending Thursday's slide.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CIGL","BK4139","CAPR","BK4165","QTTB"],"gpt_icon":0},{"id":"2550634756","title":"Inventiva Names Jason Campagna Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2550634756","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550634756?lang=en_us&edition=fundamental","pubTime":"2025-07-10 04:36","pubTimestamp":1752093365,"startTime":"0","endTime":"0","summary":"Inventiva (IVA) said late Wednesday it appointed Jason Campagna as chief medical officer and president of research and development.Campagna succeeds Michael Cooreman, who is departing as chief medical","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["QTTB","BK4139","IVA"],"gpt_icon":0},{"id":"2550666876","title":"Inventiva SA Appoints Jason Campagna as Chief Medical Officer and Martine Zimmermann as EVP of Regulatory Affairs Amid Leadership Transition","url":"https://stock-news.laohu8.com/highlight/detail?id=2550666876","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550666876?lang=en_us&edition=fundamental","pubTime":"2025-07-10 04:05","pubTimestamp":1752091523,"startTime":"0","endTime":"0","summary":"Inventiva SA Appoints Jason Campagna as Chief Medical Officer and Martine Zimmermann as EVP of Regulatory Affairs Amid Leadership Transition. Inventiva SA has announced leadership changes with the appointment of Jason Campagna, MD, PhD, as President of Research and Development and Chief Medical Officer, and Martine Zimmermann, PharmD, as Executive Vice President of Regulatory Affairs and Quality Assurance. These appointments come as the company prepares for the NATiV3 Phase 3 study results expected in the second half of 2026. Dr. Campagna brings experience from Q32 Bio and Intercept Pharmaceuticals, while Dr. Zimmermann joins from Ipsen, where she led regulatory efforts for liver disease drugs.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal ad","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250709:nNDL1M47GL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","QTTB","LU2210149790.SGD","IE00B64PRP62.GBP","NDAQ","LU2210150020.SGD","LU2095319765.USD","IE00BKPKM429.USD","IE00B3QW5Z07.USD","BK4588","BK4139","IE00BGHQF748.EUR","BK4112"],"gpt_icon":0},{"id":"2546110862","title":"Press Release: Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2546110862","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546110862?lang=en_us&edition=fundamental","pubTime":"2025-06-25 18:59","pubTimestamp":1750849140,"startTime":"0","endTime":"0","summary":"-- Dr. Sipos is an immunologist and seasoned Immunology and Inflammation (I&I) drug developer, with over 25 years of clinical development and medical affairs leadership experience --. Prior to joining Q32 Bio, Dr. Sipos served as President and Chief Medical Officer at PRAXICO Inc., where she advised both large and emerging biopharmaceutical companies on clinical development and medical affairs initiatives across multiple therapeutic areas and development stages. Prior to PRAXICO, Dr. Sipos was Head of Immunology, Late-Stage Clinical Development at Biogen, Inc., where she established the global clinical development organization for late-stage immunology and oversaw development and regulatory activities for multiple mid- to late-stage programs. Earlier, Dr. Sipos held clinical development and medical affairs roles of increasing responsibility, with an emphasis on immunology, at Sanofi Genzyme and Eli Lilly. Dr. Sipos completed postdoctoral research at the University of Oxford, Linacre Co","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Press Release: Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer","news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QTTB","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":41,"code":"91000000","status":"200"}]}}